Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
EyeCyte logo — Partnering with esteemed institutions to pioneer new treatme...

EyeCyte

Partnering with esteemed institutions to pioneer new treatments for retinal diseases.

Founded 2005 United States La Jolla, United States 1 employees Series A Total: $3.00M Biotechnology, Health Care

General Information

Company Name EyeCyte
Founded Year 2005
Location United States La Jolla, United States
Employees 1
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with EyeCyte. To contact EyeCyte, visit eyecyte.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does EyeCyte compare?

A PDF of EyeCyte and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting EyeCyte soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About EyeCyte

EyeCyte is a biotechnology firm that partners with elite institutions like Pfizer's Bioinnovation and io therapeutics Center and The Scripps Research Institute to develop innovative treatments for retinal diseases. Since its inception in 2005, EyeCyte has maintained its focus on addressing neovascular and degenerative retinal conditions through cutting-edge therapeutics.

Headquartered in the United States, EyeCyte operates at the intersection of the Biotechnology and Health Care industries. The company's potential to revolutionize the treatment landscape in ophthalmology has attracted significant investor interest.

Notably, the last significant influx of capital was a $3.00M Series A investment on 23 June 2008, with Pfizer Venture Investments taking the lead. This strategic financial backing highlights investor confidence in EyeCyte's pioneering approach and collaborative efforts with academia and renowned institutions.

Business keywords: Retinal Diseases, Therapeutics, Research, Partnerships, Innovation, Ophthalmology, Drug Development, Pfizer, Bioinnovation, Scripps Research Institute, Neovascular Disease, Degenerative Disease, Medical Collaboration, Clinical Trials

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $3.00M 1
Pfizer Venture Investments
23 Jun 2008

EyeCyte Alternatives & Competitors

View All Alternatives
EyeCyte vs
Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. United States

Advancing Accessible Solutions for Complex Neurodegenerative Diseases

IPO
29 employees
Biotechnology, Health Care
EyeCyte vs
Neurotrope Inc.
Neurotrope Inc. United States

Developing a new approach to combating Alzheimer's disease and other neurodegenerative diseases.

Series A
3 employees
Biotechnology, Health Care
EyeCyte vs
Spinogenix, Inc.
Spinogenix, Inc. United States

Developing a new class of therapeutics for neurodegenerative and psychiatric diseases

4 employees
Biotechnology, Health Care
View all alternatives

FAQ About EyeCyte

Partnering with esteemed institutions to pioneer new treatments for retinal diseases.
EyeCyte was founded in 2005.
EyeCyte is headquartered in La Jolla, United States.
EyeCyte operates in Biotechnology and Health Care. Its work centres on Retinal Diseases, Therapeutics, Research and Partnerships.
EyeCyte has approximately 1 employees.
EyeCyte has completed 1 funding round, raising a total of $3.00M. The latest funding stage is Series A.
Top alternatives and competitors to EyeCyte include Cognition Therapeutics, Inc., Neurotrope Inc., Spinogenix, Inc., Amyl Therapeutics, Drive Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
EyeCyte and Cognition Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for EyeCyte, https://bouncewatch.com/company/eyecyte, updated 19 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes